Document Detail


Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.
MedLine Citation:
PMID:  20473136     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment in AD. Seeking to detect a biological signal of statins effect on AD, we conducted a 12-week open-label trial with simvastatin 40 mg/d and then 80 mg/d in 12 patients with AD or amnestic mild cognitive impairment and hypercholesterolemia. We quantified cholesterol precursors and metabolites and AD biomarkers of Abeta and tau in both plasma and cerebrospinal fluid at baseline and after the 12-week treatment period. We found a modest but significant inhibition of brain cholesterol biosynthesis after simvastatin treatment, as indexed by a decrease of cerebrospinal fluid lathosterol and plasma 24S-hydroxycholesterol. Despite this effect, there were no changes in AD biomarkers. Our findings indicate that simvastatin treatment can affect brain cholesterol metabolism within 12 weeks, but did not alter molecular indices of AD pathology during this short-term treatment.
Authors:
Alberto Serrano-Pozo; Gloria L Vega; Dieter Lütjohann; Joseph J Locascio; Marsha K Tennis; Amy Deng; Alireza Atri; Bradley T Hyman; Michael C Irizarry; John H Growdon
Related Documents :
19332196 - Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to lo...
16375656 - Cholesterol, copper and abeta in controls, mci, ad and the ad cholesterol-lowering trea...
20339536 - Genome-wide association of lipid-lowering response to statins in combined study populat...
15900306 - Direct comparison of dietary portfolio vs statin on c-reactive protein.
11796756 - Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cul...
12118666 - Influence of dietary calcium and phosphorus content in a fixed ratio on growth and deve...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alzheimer disease and associated disorders     Volume:  24     ISSN:  1546-4156     ISO Abbreviation:  Alzheimer Dis Assoc Disord     Publication Date:    2010 Jul-Sep
Date Detail:
Created Date:  2010-08-27     Completed Date:  2011-01-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8704771     Medline TA:  Alzheimer Dis Assoc Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  220-6     Citation Subset:  IM    
Affiliation:
Memory Disorders Unit, Department of Neurology and Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston , MA 02114, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Alzheimer Disease / drug therapy*,  metabolism
Amyloid beta-Peptides / blood,  cerebrospinal fluid
Anticholesteremic Agents / administration & dosage,  adverse effects
Biological Markers / blood*,  cerebrospinal fluid*
Brain / metabolism
Cholesterol / metabolism*
Cognition Disorders / drug therapy,  metabolism
Female
Humans
Hydroxycholesterols / blood
Hypercholesterolemia / drug therapy
Male
Middle Aged
Simvastatin / administration & dosage*,  adverse effects
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Anticholesteremic Agents; 0/Biological Markers; 0/Hydroxycholesterols; 474-73-7/24-hydroxycholesterol; 57-88-5/Cholesterol; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?
Next Document:  The predictive validity of the 10/66 dementia diagnosis in Chennai, India: a 3-year follow-up study ...